Tokyo, Feb. 28 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060733) titled 'A Study on the Significance of Combining Kampo Medicine with the Molecular Targeted Drug Lenvatinib for Unresectable Thyroid Cancer and Related Drug Interactions' on Feb. 28.
Study Type:
Interventional
Study Design:
Basic Design - Parallel
Randomization - Non-randomized
Blinding - Open -no one is blinded
Control - No treatment
Primary Sponsor:
Institute - Ito Hospital
Condition:
Condition - Thyroid cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To investigate the significance of combining Kampo medicine with supportive therapy during lenvatinib treatm...